No Data
Cell seed ETC [Stocks with charm seen from changes in Volume]
Stock closing prices compared to the previous day Volume *<7477> Muraki 139,815,876,500 *<4735> Kyojin 34,226,858,400 *<4438> Welby 33,010,233,200 *<6467> Nichidai 36,626,301,500 *<4031> Katakura Co-op 8,824,198,000 *<9557> Air Cross 4,329,172,100 *<6150> Takeda Machinery 347,529,546,200 *<302A> B-style HD 12,822,103,200 *<2162>
Cell Seed and others continue to rank, with a sharp rise in Qualips spreading interest in drug discovery-related stocks.
CellSeed <7776> is ranked (as of 14:32). It has reached the daily limit up. Qualips <4894> announced that it has applied for approval to manufacture and sell regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, leading to a sharp rise to the limit up Buy indication, and interest in drug discovery-related stocks is expanding. CellSeed disclosed the start of clinical trials for allogeneic cartilage cell sheets on March 24, and it seems that there is also some buying due to reassessment. Volume change rate top [as of April 8, 14:32] (straight)
Stocks that moved and those that were traded in the front market.
*Fujihd <4676> 3037 +151.5 Continuing to increase holdings in Renos Stocks. *Japan Steel Works <5631> 4810 +244 The day before, SMBC Nikko Securities raised the Target Price. *Goodcom Asset <3475> 1104 +49 Continuing to view the commemorative benefits as a material factor. *Rohto Pharmaceutical <4527> 2247 +87 Asset Value has requested a reduction in the regenerative medicine business. *Kobe Bussan <3038> 3959 +136 Seeing the rise as a reason to Buy. *PalGroup
Stocks hitting the upper and lower limits before the market.
■Limit up <1684> WisdomTree Broad Listed ETF <2721> J Holdings <318A> VIX Short-Term Futures Index ETF <5241> Japan OA Research Institute <7776> CellSeed ■Limit down * Includes temporary limit up and down (indicative price).
Even with the start of the new fiscal year, active buying of leading stocks is likely to continue to be restrained.
This week, trading will primarily focus on short-term investments in bio-related stocks and IPOs as the new fiscal year begins. However, due to the implementation of additional tariffs by the US on April 2, along with strong concerns about the subsequent impact on the real economy, it is believed that active buying cannot be expected given the prevailing uncertainty. The Emerging Markets, centered on domestic demand, seem to be relatively stable compared to the Main Board market, but there is no feeling that the main indices in the Growth market will rise significantly. The Growth Market 250 Index has narrowed its gains.
CellSeed: Extraordinary Report
